Pembroke Management LTD Takes Position in Bruker Corporation $BRKR

Key Points

• Pembroke Management LTD acquired a new stake in Bruker Corporation, purchasing 247,812 shares valued at approximately $10.34 million, representing about 0.16% of the company's stock.
• Bruker has seen a series of adjustments from institutional investors, with ownership by such entities totaling 79.52% of the company's shares.
• The company recently declared a $0.05 quarterly dividend, payable on October 3rd, with an annual yield of 0.6% and a dividend payout ratio of 38.46%.

Pembroke Management LTD purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 247,812 shares of the medical research company's stock, valued at approximately $10,344,000. Pembroke Management LTD owned about 0.16% of Bruker as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BRKR. Raymond James Financial Inc. purchased a new stake in shares of Bruker during the fourth quarter valued at approximately $661,000. Tower Research Capital LLC TRC grew its holdings in shares of Bruker by 58.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,257 shares of the medical research company's stock valued at $425,000 after buying an additional 2,687 shares during the last quarter. Stifel Financial Corp boosted its holdings in Bruker by 2.0% in the fourth quarter. Stifel Financial Corp now owns 24,926 shares of the medical research company's stock worth $1,461,000 after purchasing an additional 480 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Bruker by 63.0% in the fourth quarter. Hsbc Holdings PLC now owns 25,574 shares of the medical research company's stock worth $1,499,000 after purchasing an additional 9,888 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Bruker by 3.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 549,490 shares of the medical research company's stock worth $32,212,000 after purchasing an additional 19,844 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BRKR shares. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Wells Fargo & Company dropped their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Bank of America dropped their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Citigroup dropped their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Finally, The Goldman Sachs Group dropped their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Bruker currently has an average rating of "Hold" and a consensus price target of $51.30.

Insiders Place Their Bets

In other news, CEO Frank H. Laukien acquired 2,608 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were purchased at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the transaction, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.30% of the company's stock.

Bruker Stock Down 0.4%

BRKR opened at $33.46 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker Corporation has a 1-year low of $30.00 and a 1-year high of $72.94. The company has a market capitalization of $5.08 billion, a PE ratio of 64.35, a PEG ratio of 2.78 and a beta of 1.16. The firm's 50 day simple moving average is $38.12 and its two-hundred day simple moving average is $40.46.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. During the same quarter in the previous year, the business posted $0.52 earnings per share. The firm's revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.